Evaluates the psychometric properties (validity and reliability) of the FSDS-DAO scale used as an efficacy endpoint in bremelanotide's phase 2b clinical trial. Confirms the FSDS-DAO has adequate measurement properties for assessing sexual distress in HSDD clinical trials, supporting its use as a validated patient-reported outcome tool for regulatory submissions.
Derogatis, Leonard R; Revicki, Dennis A; Rosen, Raymond C; Jordan, Robert; Lucas, Johna; Spana, Carl